Antihypertensive drugs interacting with central imidazoline (I1)-receptors

Bibliography

• CHALMERS JP, PILOWSKI PM: Brain stem and bulbospi-nal neuro-transmitter systems in the control of blood pressure. J. Hypertens. (1991) 9:675–694.
   PubMed Web of Science ®Google Scholar
• VAN ZWIETEN PA, CHALMERS JP: Different types of cen-trally acting antihypertensives and their targets in the central nervous system. Cardiovasc. Drugs Ther. (1994) 8:787–799.
   PubMed Web of Science ®Google Scholar
• VAN ZWIETEN PA, THOOLEN MJMC, TIMMERMANS PBMWM: The hypotensive activity and side-effects of methyldopa, clonidine and guanfacine. Hypertension (1984) 6 (Suppl. 11):28–33.
   Google Scholar
• VAN ZWIETEN PA, THOOLEN MJMC, TIMMERMANS PBMWM: The pharmacological base of the hypotensive activity and side-effects of a-methyl-DOPA, clonidine and guanfacine. Hypertension (1984) 6:11–28.
   Google Scholar
• JULIUS S: Sympathetic overactivity and the pathophysi-ology of coronary risk in hypertension. Cardiovasc. Risk Factors (1995) 5 (Suppl. 1):2–10.
   Google Scholar
• BOUSQUET P, FELDMAN J, SCHWARTZ J et al.: Central cardiovascular effects ofa-adrenergic drugs: differ-ence between catechol-amines and imidazolines. J. Pharmacol. Exp. Ther. (1984) 230:232–236.
   PubMed Web of Science ®Google Scholar
• FELDMAN J, TIBIRICA E, BRICCA G et al: Evidence for the involvement of imidazoline receptors in the central hypotensive effect of rilmenidine in the rabbit. Br. J. Pharmacol. (1990) 100:600–604.
   PubMed Web of Science ®Google Scholar
• MICHEL MC, ERNSBERGER P: Keeping an eye on the I site: Imidazoline-preferring receptors. Trends Pharma-col. ScL (1992) 13:369–370.
   PubMed Web of Science ®Google Scholar
• ERNSBERGER P, FRIEDMAN FE, KOLETSKY RJ: The Ii-im-idazoline receptor: from binding site to therapeutic target in cardiovascular disease. J. Hypertens. (1997) 15 (Suppl. 1):S9–S23.
   Google Scholar
• MICHEL MC, INSEL PA: Are there multile imidazoline binding sites? Trends Pharmacol ScL (1989):342–344.
   Google Scholar
• PARINI A, MOUDANOS CG, PIZZINAT N, LANIER SM: The elusive family of imidazoline binding sites. Trends Pharmacol. ScL (1996) 17:13–16.
   PubMed Web of Science ®Google Scholar
• ERNSBERGER P, DAMON TH, GRAFF LM: A centrally act-ing antihypertensive agent is a selective ligand for Ii-imidazoline sites. J. Pharmacol. Exp. Ther. (1993) 264:172–182.
   PubMed Web of Science ®Google Scholar
• BOUSQUET P, REID JL: Imidazoline receptors in a com-prehensive approach to hypertension. J. Cardiovasc. Pharmacol. (1995) 26 (Suppl. 2):S1–S67.
   Google Scholar
• HEAD GA, BURKE SB: Importance of noradrenergic and serotonergic pathways in the cardiovascular actions of rilmenidine and clonidine. J. Cardiovasc. Pharmacol (1991) 18:819–826.
   PubMed Web of Science ®Google Scholar
• BOUSQUET P: Recent advances in imidazoline receptor research. Exp. Opin. Invest. Drugs (1995) 4:431–442.
   Google Scholar
• REGUNATHAN S, REIS DJ: Imidazoline receptors and their endogenous ligands. Ann. Rev. Pharmacol. Toxicol (1996) 36:511–544.
   PubMed Web of Science ®Google Scholar
• MIRALLES A, OLMOS G, SASTRE M et al.: Discriminationand pharmacolo5ical characterization of I2-imid-azoline sites with [ 1-1]-idazoxan and a2-adrenoceptors with [311]-11X 821002 (2-methoxy-idazoxan) in the hu-man and rat brains. J. Pharmacol. Exp. Ther. (1993) 264:1187–1197.
   PubMedGoogle Scholar
• ERNSBERGER P, MEELEY MP, MANN JJ, REIS DJ: Clonidine binds to imidazoline binding sites as well as a2-adrenoceptors in the ventrolateral medulla. Eur. Pharmacol. (1987) 134:1–13.
   PubMed Web of Science ®Google Scholar
• SCHULZ A, HASSELBLATT A: An insulin-releasing prop-erty of imidazoline derivatives is not limited to com-pounds that block adrenoceptors. Naunyn Schmiedeb. Arch. Pharmacol. (1989) 340:321–327.
   PubMed Web of Science ®Google Scholar
• PENNER SB, SMYTH D: The role of the peripheral sym-pathetic nervous system in the natriuresis following central administration of an Ii-imidazoline agonist, moxonidine. Br. J. Pharmacol. (1995) 116:2631–2636.
   PubMed Web of Science ®Google Scholar
• WENZEL RR, QUI S, SPIEKER L, LIISCHER TF, NOLL G: Moxonidine decreases both cardiac and peripheral sympathetic activity in healthy volunteers. Kidney Blood Press. Res. (1996) 19:63. (Abstract).
   Google Scholar
• HEAD GH: Central monoamine systems and new anti-hypertensive agents. Clin. Exp. Hypertens. (1995) 17:141–152.
   PubMed Web of Science ®Google Scholar
• ATLAS D, BURSTEIN Y: Isolation and partial purifica-tion of a clonidine displacing brain substance. Eur. J. Biochem. (1984) 144:287–293.
   PubMedGoogle Scholar
• BOUSQUET P, FELDMAN J, ATLAS D: An endogenous,non-catecholamine clonidine antagonist increases mean arterial blood pressure. Eur. J. Pharmacol. (1986) 124:167–170.
   PubMed Web of Science ®Google Scholar
• LI G, REGUNATHAN S, BARROW CJ, ESHRAGHI J, COOPER R, REIS DJ: Agmatine: an endogenous clonidine-displacing substance in the brain. Science (1994) 263:966–969.
   PubMed Web of Science ®Google Scholar
• PINTHONG D, WRIGHT IK, HANMER C et al.: Agmatine recognizes a2-adrenoceptor binding sites but neither activates nor inhibits a2-adrenoceptors. Naunyn-Schmiedeb. Arch. Pharmacol (1995) 351:10–16.
   Google Scholar
• SUN MK, REGUNATHAN S, REIS DJ: Cardiovascular re-sponses to agmatine, a clonidine displacing substance, in anesthetized rat. Clin. Exp. Hypertens. (1995) 17:115–128.
   PubMed Web of Science ®Google Scholar
• KAAN EC, BRUCKNER R, FROHLY P et al: Effects of agma-tine and moxonidine on glucose metabolism. Cardio-vasc. Risk Fact. (1995) 5 (Suppl. 1):19–27.
   Google Scholar
• BRICCA G, ZHANG J, GRENEY H et al.: Relevance of the use of [311]-clonidine to identify imidazoline receptors in the rabbit brain stem. Br. J. Pharmacol. (1993) 110:1537–1543.
   PubMed Web of Science ®Google Scholar
• PARINI A, BOUSQUET P: From a2-adrenoceptors to imi-dazoline preferring receptors. Fundam. Gun. Pharma-col. (1992) 6 (Suppl. 1):1S–635.
   Google Scholar
• ERNSBERGER P, HAXHIU MA, GRAFF LM et al.: A novel mechanism of action of hypertension control: moxo-nidine as a selective Ii-imidazoline agonist. Cardiovasc. Drugs Ther. (1994) 8:27–41.
   PubMed Web of Science ®Google Scholar
• DE VOS H, BRICCA G, DE KEYSER J et al.: Imidazoline re-ceptors, non-adrenergic idazoxan binding sites and a2-adrenoceptors in the human central nervous sys-tem. Neuroscience (1994) 59:589–598.
   Google Scholar
• ZIEGLER D, HAXHIU MA, KAAN EC, PAPP JG, ERNS-BERGER P: Pharmacology of moxonidine, an azoline receptor agonist. J. Cardiovasc.Pharmacol. (1996) 27 (Suppl. 3):S26–537.
   Google Scholar
• CHAN CKS, HEAD GA: Relative importance of centralimidazoline receptors for the antihypertensive effects of moxonidine and rilmenidine. J. Hypertens. (1996) 14:855–864.
   PubMed Web of Science ®Google Scholar
• HAXHIU MA, DRESHAJ I, SCHAFER SG, ERNSBERGER P: Selective antihypertensive action of moxonidine is mediated mainly by It-imidazoline receptors in the rostral ventrolateral medulla. J. Cardiovasc. Pharmacol. (1994) 24 (Suppl. 1):S1–S8.
   Google Scholar
• URBAN R, SZABO B, STARKE K: Is the sympathoinhibi-tory effect of rilemnidine mediated by a 2-adrenoceptors or imidazoline receptors? J. Pharmacol. Exp. Ther. (1994) 270:572–578.
   PubMed Web of Science ®Google Scholar
• URBAN R, SZABO B, STARKE K: Involvement of a2-adrenoceptors in the cardiovascular effects of moxo-nidine. Eur. J. Pharmacol (1995) 282:19–28.
   PubMed Web of Science ®Google Scholar
• LEPRAN I, PAPP JG: Effect of moxonidine on arrhyth-mias induced by coronary artery occlusion and reper-fusion. J. Cardiovasc. Pharmacol. (1994) 24 (Suppl. 1):S9–S15.
   Google Scholar
• MAMMOTO T, KAMIBAYASHI T, HAYASHI Y et al.: Ril-menidine prevents epinephrine-induced arrhythmias in halothane-anesthetized dogs. J. Cardiovasc. Pharma-col. (1995) 26 (Suppl. 2):S40–S43.
   Google Scholar
• N'GUYEN VAN CAO A, LEVY B, SLAMA R: Non-invasivestudy of cardiac structure and function after rilmen-idine for essential hypertension. Am. J .Cardiol. (1988) 61:72D–75D.
   Google Scholar
• EICHSTADT H, RICHTER W, BADER W: Demonstration ofhypertrophy regression with magnetic resonance to-mography under the new adrenergic inhibitor moxo-nidine. Cardiovasc. Drugs Ther. (1989) 3:583–587.
   Google Scholar
• THOOLEN MJMC, TIMMERMANS PBMWM, VAN ZWIETENPA: Discontinuation syndrome after continuous infu-sion of clonidine in the spontaneously hypertensive rat. Life Sci. (1981) 28:2103–2109.
   PubMed Web of Science ®Google Scholar
• THOOLEN MJMC, TIMMERMANS PBMWM, VAN ZWIETENPA: Guanfacine and clonidine: antihypertensive and withdrawal characteristics after continuous infusion and its interruption in the spontaneously hyperten-sive and normotensive rat. Naunyn-Schmiedeb. Arch. Pharmacol. (1982) 319:82–86.
   Google Scholar
• WEBSTER J, KOVK HF: Rebound and aspects of toler-ability of centrally acting antihypertensive drugs. J. Cardiovasc. Pharmacol. (1996) 27 (Suppl. 3):S49–S54.
   Google Scholar
• JARROT B, LEWIS SJ, DOYLE AE, LOUIS WJ: Effects of con-tinuous infusions (10 days) and cessation of infusions of clonidine and rilmenidine in hypertensive rats. Am. Cardiol (1988) 61:39D–44D.
   Google Scholar
• PENNER SB, SMYTH D: Sodium excretion following cen-tral administration of an imidazoline receptor agonist, moxonidine. Br. J. Pharmacol (1994) 112:1089–1094.
   PubMed Web of Science ®Google Scholar
• SMYTH DD, PENNER BS: Renal Ii-imidazoline receptor-selective compounds mediate natriuresis in the rat. J. Cardiovasc. Pharmacol (1995) 26 (Suppl. 2):S63–S67.
   Google Scholar
• ERNSBERGER P, KOLETSKY RJ, COLLINS LA, BEDOL D: Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnor-malities by a central sympatholytic agent. Cardiovasc. Drugs Ther. (1996) 10:275–282.
   PubMed Web of Science ®Google Scholar
• SCHAFER SG, CHRISTEN MO, ERNSBERGER P: The sec-ond generation of centrally acting drugs. J. Cardiovasc. Pharmacol. (1992) 20 (Suppl. 4) :vii-viii.
   Google Scholar
• KOENIG-BERARD E, TIERNEY C, BEAU C et al: Cardiovas-cular and central nervous system effects of rilmen-idine in rats. Am.J.Cardiol. (1988) 61:22D–23D.
   Google Scholar
• PRICHARD BNC: Clinical pharmacology of moxo-nidine. In: The h-Imidazoline Receptor Agonist Moxo-nidine: A New Antihypertensive. (2nd Edition) van Zwieten PA, Hamilton CA, Julius S, Prichard BNC (Eds.), Roy. Soc. Med. Press London 1996; pp.31–47.
   Google Scholar
• WEIMANN HJ, RUDOLPH M: Clinical pharmacokineticsof moxonidine. J. Cardiovasc. Pharmacol (1992) 20 (Suppl. 4):S37–S41.
   Google Scholar
• KIRCH W, HUTT HJ, PLANITZ V: The influence of renalfunction on clinical pharmacokinetics of moxonidine. Pharmacokin. (1988) 15:245–253.
   PubMed Web of Science ®Google Scholar
• APARICIO M, DRATWA M, EL ESPER N: Pharmacokinet-ics of rilmenidine in patients with chronic renal insuf-ficiency and in hemodialysis patients. Am. J. Cardiol. (1994) 74:43A–50A.
   Google Scholar
• UNITED KINGDOM WORKING PARTY ON RILMENIDINE:Rilmenidine in mild-to-moderate essential hyperten-sion. Curr. Ther. Res. (1990) 1:194–211.
   Google Scholar
• MITROVIC V, PATYNA W, HeJTING J, SCHLEPPER W: Hae-modynamic and neurohormonal effects of moxo-nidine in patients with essential hypertension. Cardiovasc. Drugs Ther. (1991) 5:967–972.
   PubMed Web of Science ®Google Scholar
• PRICHARD BNC: Clinical experience with moxonidine.In: The h-Imidazoline Receptor Agonist Moxonidine: A New Antihypertensive. (2nd Edition) van Zwieten PA, Hamilton CA, Julius S, Prichard BNC (Eds.). Roy. Soc. Med. Press Ltd. London (1996): 49–77.
   Google Scholar
• PRICHARD BNC, GRAHAM BR: Effective antihyperten-sive therapy: blood pressure control with moxo-nidine. J. Cardiovasc.Pharma-col. (1996) 27 (Suppl. 3): S38–S48.
   Google Scholar
• RUPP H, MAISCH B, BRILLA CG: Drug withdrawal and re-bound hypertension: differential action of the central antihypertensive drugs moxonidine and clonidine. Cardiovasc. Drugs Ther. (1996) 10:251–262.
   PubMed Web of Science ®Google Scholar
• CRISP P, FAULDS D: Moxonidine. Drugs (1992) 44:993–1012.
   PubMed Web of Science ®Google Scholar
• MORRISON PJ, CORCORAN C, VIVET P: Effect of rilmen-idine on alertness. JAMA (French Ed.) Special Issue (July 27–28, 1990).
   Google Scholar
• FIORENTINI C, GUILLET C, GUAZZI M: A multicentre double-blind trial comparing rilmenidine 1 mg and hydrochlorothiazide in 244 patients. Arch. Mal. Coeur Vaiss. (1989) 82:39–46.
   PubMedGoogle Scholar
• KRENTZ AJ, EVANS AJ: Selective imidazoline receptor agonists for metabolic syndrome. Lancet (1998) 351:152–154.
   PubMed Web of Science ®Google Scholar
• ROSEN P, OHLY P, GLEICHMAN H: Experimental benefit of moxonidine on glucose metabolism and insulin se-cretion in the fructose-fed rat. J. Hypertens. (1997) 15 (Suppl. 1):S31–S38.
   Google Scholar
• MANOLIS AJ, OLYMPIOS C, SIFAKI M et al.: Suppressing sympathetic activation in congestive heart failure. Hy-pertension (1995) 26:719–724.
   PubMed Web of Science ®Google Scholar
• SWEDBERG K: Results of a Phase II dose response trial of moxonidine in CHF. In: Sympathetic Neurohumoral Modulation In Cardiovascular Disease. Esler M (Ed.), Sym-posium, Cologne (1997).
   Google Scholar